Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers

被引:0
作者
Branchford, Brian [1 ,2 ,3 ]
Clark, Kim [4 ]
Stanford, Richard H. [5 ]
Garner, Denise A. [6 ]
Huang, Shirley P. [5 ]
Wolford, Eric [4 ]
机构
[1] Versiti Med Sci Inst, Milwaukee, WI USA
[2] Med Coll Wisconsin, Blood Res Inst, Milwaukee, WI USA
[3] Childrens Wisconsin, Milwaukee, WI USA
[4] Kedrion Biopharm Inc, Ft Lee, NJ 07024 USA
[5] AESARA INC, Durham, NC USA
[6] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
关键词
burden of illness; caregivers; hereditary factor X deficiency; prophylaxis; quality of life; survey; DISORDERS; DIAGNOSIS;
D O I
10.1097/MBC.0000000000001275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hereditary factor X deficiency (HFXD) is a rare bleeding disorder causing delayed haemostasis and potentially life-threatening bleeds. Patient/caregiver burden and diagnosis path have not been well characterized.The aim of this study was todescribe the diagnosis path, disease burden, and HFXD impact on quality of life (QoL) in patients and caregivers.This was a prospective, cross-sectional, web-based survey of patients with HFXD and caregivers addressing the patient/caregiver experience, QoL, humanistic and unmet needs.Thirty patients and 38 caregivers completed the survey with mean ages 24.7 and 44.6 years, respectively. Mean age at diagnosis was 4.1 years. The diagnostic process was somewhat/very difficult for 23% of patients and 26% of caregivers. Approximately half (53%) received single factor replacement (SFR) as prophylaxis or on-demand. Most patients (71%) reported regular prophylaxis treatment. Over one-fourth (27%) reported treatment with fresh frozen plasma. Bleeding episodes were less common in patients using SFR versus non-SFR: three bleeds or fewer were reported by 92% SFR and 75% non-SFR patients. HFXD patients reported low well being in work/school/social activities with mean HFXD-adapted Hemophilia Well being Index. Patient symptoms negatively impacted caregiver burden with a mean HFXD-adapted Hemophilia Caregiver Index (+/- SD) of 15.9 (4.6), but also unexpectedly had a positive impact on self-worth and inner strength.To our knowledge, this is the first study to assess patient and caregiver burden of HFXD and impact on QoL. Improvements in symptom recognition, prompt diagnosis, and adherence to expert recommendations for treatment could improve QoL and decrease burden on HFXD patients and caregivers.The aim of this study was todescribe the diagnosis path, disease burden, and HFXD impact on quality of life (QoL) in patients and caregivers.This was a prospective, cross-sectional, web-based survey of patients with HFXD and caregivers addressing the patient/caregiver experience, QoL, humanistic and unmet needs.Thirty patients and 38 caregivers completed the survey with mean ages 24.7 and 44.6 years, respectively. Mean age at diagnosis was 4.1 years. The diagnostic process was somewhat/very difficult for 23% of patients and 26% of caregivers. Approximately half (53%) received single factor replacement (SFR) as prophylaxis or on-demand. Most patients (71%) reported regular prophylaxis treatment. Over one-fourth (27%) reported treatment with fresh frozen plasma. Bleeding episodes were less common in patients using SFR versus non-SFR: three bleeds or fewer were reported by 92% SFR and 75% non-SFR patients. HFXD patients reported low well being in work/school/social activities with mean HFXD-adapted Hemophilia Well being Index. Patient symptoms negatively impacted caregiver burden with a mean HFXD-adapted Hemophilia Caregiver Index (+/- SD) of 15.9 (4.6), but also unexpectedly had a positive impact on self-worth and inner strength.To our knowledge, this is the first study to assess patient and caregiver burden of HFXD and impact on QoL. Improvements in symptom recognition, prompt diagnosis, and adherence to expert recommendations for treatment could improve QoL and decrease burden on HFXD patients and caregivers.The aim of this study was todescribe the diagnosis path, disease burden, and HFXD impact on quality of life (QoL) in patients and caregivers. This was a prospective, cross-sectional, web-based survey of patients with HFXD and caregivers addressing the patient/caregiver experience, QoL, humanistic and unmet needs.Thirty patients and 38 caregivers completed the survey with mean ages 24.7 and 44.6 years, respectively. Mean age at diagnosis was 4.1 years. The diagnostic process was somewhat/very difficult for 23% of patients and 26% of caregivers. Approximately half (53%) received single factor replacement (SFR) as prophylaxis or on-demand. Most patients (71%) reported regular prophylaxis treatment. Over one-fourth (27%) reported treatment with fresh frozen plasma. Bleeding episodes were less common in patients using SFR versus non-SFR: three bleeds or fewer were reported by 92% SFR and 75% non-SFR patients. HFXD patients reported low well being in work/school/social activities with mean HFXD-adapted Hemophilia Well being Index. Patient symptoms negatively impacted caregiver burden with a mean HFXD-adapted Hemophilia Caregiver Index (+/- SD) of 15.9 (4.6), but also unexpectedly had a positive impact on self-worth and inner strength.To our knowledge, this is the first study to assess patient and caregiver burden of HFXD and impact on QoL. Improvements in symptom recognition, prompt diagnosis, and adherence to expert recommendations for treatment could improve QoL and decrease burden on HFXD patients and caregivers.The aim of this study was todescribe the diagnosis path, disease burden, and HFXD impact on quality of life (QoL) in patients and caregivers.This was a prospective, cross-sectional, web-based survey of patients with HFXD and caregivers addressing the patient/caregiver experience, QoL, humanistic and unmet needs.Thirty patients and 38 caregivers completed the survey with mean ages 24.7 and 44.6 years, respectively. Mean age at diagnosis was 4.1 years. The diagnostic process was somewhat/very difficult for 23% of patients and 26% of caregivers. Approximately half (53%) received single factor replacement (SFR) as prophylaxis or on-demand. Most patients (71%) reported regular prophylaxis treatment. Over one-fourth (27%) reported treatment with fresh frozen plasma. Bleeding episodes were less common in patients using SFR versus non-SFR: three bleeds or fewer were reported by 92% SFR and 75% non-SFR patients. HFXD patients reported low well being in work/school/social activities with mean HFXD-adapted Hemophilia Well being Index. Patient symptoms negatively impacted caregiver burden with a mean HFXD-adapted Hemophilia Caregiver Index (+/- SD) of 15.9 (4.6), but also unexpectedly had a positive impact on self-worth and inner strength.To our knowledge, this is the first study to assess patient and caregiver burden of HFXD and impact on QoL. Improvements in symptom recognition, prompt diagnosis, and adherence to expert recommendations for treatment could improve QoL and decrease burden on HFXD patients and caregivers.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 20 条
  • [1] HaemoPREF: Further evaluation of patient perception and preference for treatment in a real world setting
    Bonanad, S.
    Schulz, M.
    Gordo, A.
    Spurden, D.
    Cicchetti, M.
    Cappelleri, J. C.
    Tolley, C.
    Staunton, H.
    Brohan, E.
    [J]. HAEMOPHILIA, 2017, 23 (06) : 884 - 893
  • [2] Diagnosis and treatment of inherited factor X deficiency
    Brown, D. L.
    Kouides, P. A.
    [J]. HAEMOPHILIA, 2008, 14 (06) : 1176 - 1182
  • [3] Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life
    Bushnell, Donald M.
    Martin, Mona L.
    Moore, Keith A.
    Richter, Holly E.
    Rubin, Arkady
    Patrick, Donald L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (12) : 2745 - 2755
  • [4] Factor X deficiency, National Organization for Rare Disorders
  • [5] hemophilia, Factor X Deficiency
  • [6] Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene
    Herrmann, F. H.
    Auerswald, G.
    Ruiz-Saez, A.
    Navarrete, M.
    Pollmann, H.
    Lopaciuk, S.
    Batorova, A.
    Wulff, K.
    [J]. HAEMOPHILIA, 2006, 12 (05) : 479 - 489
  • [7] Factor X Deficiency
    Menegatti, Marzia
    Peyvandi, Flora
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2009, 35 (04) : 407 - 415
  • [8] Guideline for the diagnosis and management of the rare coagulation disorders A United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology
    Mumford, Andrew D.
    Ackroyd, Sam
    Alikhan, Raza
    Bowles, Louise
    Chowdary, Pratima
    Grainger, John
    Mainwaring, Jason
    Mathias, Mary
    O'Connell, Niamh
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (03) : 304 - 326
  • [9] National Hemophilia Foundation, 2023, MASAC Document 276 - MASAC Recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders
  • [10] National Organization for Rare Disorders (NORD), 2020, Barriers to rare disease diagnosis, care, and treatment in the US